source
- Roche partners with Dualitas Therapeutics in up to $1 billion deal to screen bispecific antibodies for immune diseasesRoche has committed $36.5 million up front to biotechnology startup Dualitas Therapeutics under a research partnership that could total up to $1 billion in milestone payments and royalties. The agr…
- Bristol Myers ends $100M Phase 1 cancer ADC programBristol Myers Squibb announced it has discontinued development of its Phase 1 antibody-drug conjugate candidate BMS-986497/ORM-6151. The decision follows a review of early clinical data, leading t…